Want to track TNYA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
TNYA closed today lower at $0.82, a decrease of -2.506% from yesterday's close, completing a monthly decrease of -9.8234% or -$0.09. Over the past 12 months, TNYA stock gained 12.643%.
TNYA is not paying dividends to its shareholders.
The last earnings report, released on Mar 24, 2026, exceeded the consensus estimates by 0.1375%. On average, the company has surpassed earnings expectations by 0.0958%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Seekingalpha | 1 month ago
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM Transcript
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM Transcript
Seekingalpha | 1 month ago
Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVC Transcript
Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVC Transcript
Seekingalpha | 2 months ago
Tenaya Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DH Dinan Hu R Squared Ltd | 11,208 | $7,761 | $9,307.12 | $1,546.12 | 19.92% |
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 33,200 | $22,988 | $27,569.28 | $4,581.28 | 19.93% |
| RO Regan O'Neill Burkehill Global Management LP | 2M | $1.42M | $1.67M | $249,600 | 17.54% |
 Li Peng China Universal Asset Management Co. Ltd. | 38,466 | $27,152.08 | $32,357.6 | $5,205.52 | 19.17% |
| JG John Ginter Callan Family Office LLC | 50,061 | $30,489.97 | $41,070.04 | $10,580.07 | 34.7% |
Tenaya Therapeutics, Inc. (TNYA) FAQ
What is the stock price today?
The current price is $0.82.
On which exchange is it traded?
Tenaya Therapeutics, Inc. is listed on NASDAQ (NGS).
What is its stock symbol?
The ticker symbol is TNYA.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 144.05M.
Has Tenaya Therapeutics, Inc. ever had a stock split?
No, there has never been a stock split.
Tenaya Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Faraz Ali CEO | NASDAQ (NGS) Exchange | 87990A106 CUSIP |
| US Country | 70 Employees | - Last Dividend | - Last Split | 30 Jul 2021 IPO Date |
Overview
Tenaya Therapeutics, Inc. is a pioneering biotechnology company based in the United States, dedicated to the discovery, development, and delivery of innovative therapies for heart disease. Utilizing advanced platforms in cellular regeneration, gene therapy, and precision medicine, Tenaya aims to transform the treatment landscape for patients suffering from various heart conditions. Since its establishment in 2016, the company has positioned itself at the forefront of cardiological research and therapy development, operating from its headquarters in South San Francisco, California.
Products and Services
- TN-201: An adeno-associated virus (AAV)-based gene therapy aimed at treating genetic hypertrophic cardiomyopathy (gHCM) caused by mutations in the MYBPC3 gene. This therapy is designed to address the genetic root of gHCM by providing a normal copy of the MYBPC3 gene to restore cardiac function.
- TN-301: A small molecule that inhibits histone deacetylase 6 (HDAC6), intended for use in patients with heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). By targeting HDAC6, TN-301 seeks to alleviate the symptoms and progression of these complex heart diseases.
- TN-401: Another AAV-based gene therapy developed for the treatment of genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by mutations in the plakophilin 2 (PKP2) gene. This innovative approach aims to correct the underlying genetic abnormality, potentially providing a durable treatment option for those affected by gARVC.
- AAV-based gene therapy for DCM: Focused on delivering the dwarf open reading frame (DWORF) gene directly to the heart, this therapy is being developed for dilated cardiomyopathy (DCM). The DWORF gene plays a crucial role in cardiac muscle function, and its delivery could help in restoring heart muscle function in DCM patients.
- Reprogramming program: A cutting-edge AAV-based approach aimed at cardiac regeneration. This program is designed to replace heart cells lost due to myocardial infarction, offering new hope for heart failure patients. By reprogramming cells within the heart, this strategy could revolutionize the treatment of heart failure, providing a novel avenue for cardiac repair and regeneration.
Contact Information
Address: 171 Oyster Point Boulevard
Phone: 650 825 6900
Website: https://www.tenayatherapeutics.com
